Business Description
Shanghai Pharmaceuticals Holding Co Ltd
NAICS : 446110
ISIN : US81943R1005
Share Class Description:
SHPMY: ADR repr Class HCompare
Compare
Traded in other countries / regions
601607.China02607.Hong KongSHPMF.USAS1R.Germany IPO Date
2013-03-04Description
Shanghai Pharmaceuticals is the second-largest medical distributor in China by revenue. It is vertically integrated and provides healthcare services in research and development, manufacturing, distribution, and retail. As of 2023, medical distribution is the largest segment, accounting for 89.8% of total revenue. It also has coverage of 31 provinces and cities nationwide.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.76 | |||||
Equity-to-Asset | 0.32 | |||||
Debt-to-Equity | 0.7 | |||||
Debt-to-EBITDA | 5.7 | |||||
Interest Coverage | 5.75 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.09 | |||||
Beneish M-Score | -2.3 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.5 | |||||
3-Year EBITDA Growth Rate | -7 | |||||
3-Year EPS without NRI Growth Rate | -10.2 | |||||
3-Year FCF Growth Rate | -23.1 | |||||
3-Year Book Growth Rate | 5.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 22 | |||||
Future 3-5Y Total Revenue Growth Rate | 10.8 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 30.92 | |||||
9-Day RSI | 37.64 | |||||
14-Day RSI | 41.2 | |||||
6-1 Month Momentum % | -5.09 | |||||
12-1 Month Momentum % | -6.91 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.34 | |||||
Quick Ratio | 1.07 | |||||
Cash Ratio | 0.3 | |||||
Days Inventory | 53.4 | |||||
Days Sales Outstanding | 105.72 | |||||
Days Payable | 87.72 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 3.9 | |||||
Dividend Payout Ratio | 0.49 | |||||
3-Year Dividend Growth Rate | 11.5 | |||||
Forward Dividend Yield % | 3.9 | |||||
5-Year Yield-on-Cost % | 5.6 | |||||
3-Year Average Share Buyback Ratio | -9.2 | |||||
Shareholder Yield % | -8.21 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 11.63 | |||||
Operating Margin % | 3.58 | |||||
Net Margin % | 1.44 | |||||
FCF Margin % | -0.28 | |||||
ROE % | 5.53 | |||||
ROA % | 1.79 | |||||
ROIC % | 7.08 | |||||
ROC (Joel Greenblatt) % | 17.11 | |||||
ROCE % | 9.51 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 18.74 | |||||
Forward PE Ratio | 7.76 | |||||
PE Ratio without NRI | 16.07 | |||||
Shiller PE Ratio | 13.37 | |||||
Price-to-Owner-Earnings | 57.61 | |||||
PEG Ratio | 4.12 | |||||
PS Ratio | 0.27 | |||||
PB Ratio | 1.02 | |||||
Price-to-Tangible-Book | 1.36 | |||||
Price-to-Operating-Cash-Flow | 29.97 | |||||
EV-to-EBIT | 8.72 | |||||
EV-to-Forward-EBIT | 7.95 | |||||
EV-to-EBITDA | 8.72 | |||||
EV-to-Forward-EBITDA | 6.38 | |||||
EV-to-Revenue | 0.28 | |||||
EV-to-Forward-Revenue | 0.26 | |||||
EV-to-FCF | -97.81 | |||||
Price-to-Projected-FCF | 1.06 | |||||
Price-to-DCF (Earnings Based) | 0.69 | |||||
Price-to-Median-PS-Value | 0.8 | |||||
Price-to-Graham-Number | 0.99 | |||||
Price-to-Net-Current-Asset-Value | 3.56 | |||||
Earnings Yield (Greenblatt) % | 11.47 | |||||
FCF Yield % | -1.22 | |||||
Forward Rate of Return (Yacktman) % | 6.59 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SHPMY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shanghai Pharmaceuticals Holding Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 36,697.156 | ||
EPS (TTM) ($) | 0.713 | ||
Beta | 0.48 | ||
Volatility % | 25.47 | ||
14-Day RSI | 41.2 | ||
14-Day ATR ($) | 0.150602 | ||
20-Day SMA ($) | 7.51375 | ||
12-1 Month Momentum % | -6.91 | ||
52-Week Range ($) | 6.455 - 8.41 | ||
Shares Outstanding (Mil) | 740.82 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Shanghai Pharmaceuticals Holding Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Shanghai Pharmaceuticals Holding Co Ltd Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Shanghai Pharmaceuticals Holding Co Ltd Frequently Asked Questions
What is Shanghai Pharmaceuticals Holding Co Ltd(SHPMY)'s stock price today?
The current price of SHPMY is $7.23. The 52 week high of SHPMY is $8.41 and 52 week low is $6.46.
When is next earnings date of Shanghai Pharmaceuticals Holding Co Ltd(SHPMY)?
The next earnings date of Shanghai Pharmaceuticals Holding Co Ltd(SHPMY) is 2024-08-30 Est..
Does Shanghai Pharmaceuticals Holding Co Ltd(SHPMY) pay dividends? If so, how much?
The Dividend Yield %  of Shanghai Pharmaceuticals Holding Co Ltd(SHPMY) is 3.9% (As of Today), Highest Dividend Payout Ratio of Shanghai Pharmaceuticals Holding Co Ltd(SHPMY) was 0.63. The lowest was 0.3. And the median was 0.34. The  Forward Dividend Yield % of Shanghai Pharmaceuticals Holding Co Ltd(SHPMY) is 3.9%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |